Skip directly to Accessibility Notice

BBH
VanEck Biotech ETF

Fund Description

VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS®US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

 
 

  • Fund Ticker

    BBH

  • Exchange

    NASDAQ

  • ETF Structure

    Physical

  • Administrator

    Van Eck Associates

  • Custodian

    State Street Bank and Trust Company

  • Index Ticker

    MVBBHTR

  • Index Rebalancing

    Quarterly

 
as of 01/20/22

  • 30-Day SEC Yield

    0.38%

  • Total Net Assets

    $482.6M

  • Number of Holdings

    25

  • Options

    Available

  • Gross Expense Ratio2

    0.35%

  • Net Expense Ratio/TER2

    0.35%

  • Distribution Frequency

    Annual
Schedule a Call
How to Buy

Morningstar™ Ratings3
as of 12/31/2021

Category Overall 3 Year 5 Year
Health
3 stars of 140 funds
3 stars of 140 funds
2 stars of 130 funds

Key Points

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market cap and trading volume

  • Industry Leaders 
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation

Trading Information

  • Fund Ticker

    BBH

  • Index Total Return Ticker

    MVBBHTR

  • NAV

    BBHNV

  • Intraday NAV (IIV)4

    BBHIV

  • Shares Outstanding

    2,946,503

  • Estimated Cash

    BBHEU

  • Total Cash

    BBHTC

  • CUSIP

    92189F726

  • ISIN

    US92189F7261
Source: Bloomberg

Fees and Expenses2

  • Management Fee

    0.35%

  • Other Expenses

    --

  • Acquired Fund Fees and Expenses

    --

  • Gross Expense Ratio

    0.35%

  • Fee Waivers and
    Expense Reimbursement

    --

  • Net Expense Ratio/TER2

    0.35%
2Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses.

Investment Professionals

  • Portfolio Manager and Head of Equity ETFs
  • Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
  • Joined VanEck in 2005
  • CFA charterholder; member of the CFA Society New York
  • BA, Mathematics and Economics, New York University
  • Portfolio Manager and Analyst for Equity ETFs
  • Joined VanEck in 2007
  • Prior to his current role, held a portfolio administration position at VanEck
  • Previously, Portfolio Analyst at Evaluation Associates
  • BS, Business Administration (concentration in Financial Analysis), State University of New York at Buffalo
  • Analyst for Equity ETFs
  • Joined VanEck in 2018
  • Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
  • BS, Finance, Providence College
  • Analyst for Equity ETFs
  • Joined VanEck in 2019
  • Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
  • BS, Accounting, Hunter College

Prices as of 01/20/22

NAV/
Market Price 		Volume
30-Day Avg./
Last Trading Day 		Daily Change
NAV/
Last Price 		YTD Change
NAV/
Last Price 		Premium/
Discount 		Prem/Discount
Distribution Charts 		NAV &
Prem/Discount
History 		30-Day
Median
Bid Ask
Spread 		NAV
Chart
BBH $163.78
$163.96		 23,466
35,780		 -$1.31 / -0.79%
$-1.06 / -0.64%		 -13.46%
-13.40%
 $0.18
0.11%		 0.11%

Premium/Discount History as of 01/20/22

Calendar Year 2020 1Q 2021 2Q 2021 3Q 2021 4Q 2021 Premium/Discount Charts NAV & Prem/Discount History
Days closed at a premium 145 33 33 31 38
BBH Days closed at NAV 9 0 1 0 0
Days closed at a discount 99 28 29 33 26


Performance History: Average Annual Total Returns* (%)
View All ETFs View All Indices

1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
BBH (NAV) -3.03 -6.10 11.77 11.77 19.71 12.43 18.24 18.57
BBH (Share Price) -3.09 -6.13 11.82 11.82 19.95 12.41 18.26 18.58
MVBBHTR (Index) -3.02 -6.06 12.00 12.00 19.89 12.63 18.44 18.77
Performance Differential (NAV - Index) -0.01 -0.04 -0.23 -0.23 -0.18 -0.20 -0.20 -0.20
1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE
12/20/11
BBH (NAV) -3.03 -6.10 11.77 11.77 19.71 12.43 18.24 18.57
BBH (Share Price) -3.09 -6.13 11.82 11.82 19.95 12.41 18.26 18.58
MVBBHTR (Index) -3.02 -6.06 12.00 12.00 19.89 12.63 18.44 18.77
Performance Differential (NAV - Index) -0.01 -0.04 -0.23 -0.23 -0.18 -0.20 -0.20 -0.20

*Returns less than one year are not annualized.

The table presents past performance which is no guarantee of future results and which may be lower or higher than current performance. Returns reflect temporary contractual fee waivers and/or expense reimbursements. Had the ETF incurred all expenses and fees, investment returns would have been reduced. Investment returns and ETF share values will fluctuate so that investors' shares, when redeemed, may be worth more or less than their original cost. ETF returns assume that dividends and capital gains distributions have been reinvested in the Fund at NAV.

The "Net Asset Value" (NAV) of a VanEck Exchange Traded Fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. VanEck ETF investors should not expect to buy or sell shares at NAV.

Top 10 Holdings (%) as of 12/31/21 Daily Holdings

Total Holdings: 25
Swipe
to view
full data
Holding Name
Ticker
Shares
 Market Value
(US$) 		% of Net
Assets
Amgen Inc
AMGN US
288,081
 64,809,583 11.43
Moderna Inc
MRNA US
224,410
 56,995,652 10.05
Gilead Sciences Inc
GILD US
580,033
 42,116,196 7.43
Regeneron Pharmaceuticals Inc
REGN US
49,626
 31,339,812 5.53
Iqvia Holdings Inc
IQV US
108,414
 30,587,926 5.39
Vertex Pharmaceuticals Inc
VRTX US
138,294
 30,369,362 5.35
Illumina Inc
ILMN US
78,844
 29,995,411 5.29
Biogen Inc
BIIB US
109,559
 26,285,395 4.63
Bio-Techne Corp
TECH US
47,683
 24,668,323 4.35
Biontech Se
BNTX US
88,085
 22,708,313 4.00
Top 10 Total (%) 63.46
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 12/31/21

  • Country

    % of Net Assets
  • ■

    United States

    88.79
  • ■

    Germany

    4.00
  • ■

    Ireland

    3.53
  • ■

    China

    2.43
  • ■

    Switzerland

    1.26
  • ■

    Other/Cash

    -0.01

Sector Weightings (%) as of 12/31/21

  • Sector

    % of Net Assets
  • ■

    Health Care

    100.0
  • ■

    Other/Cash

    0.0